Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2021-12-16 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Exercise of share options and total voting rights
Share Issue/Capital Change Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS and the London Stock Exchange. The content details a specific transaction: the exercise of share options by a Non-Executive Director (Sonya Ferguson) and the resulting change in the total number of voting rights. This type of mandatory disclosure regarding insider transactions and total voting rights under UK Market Abuse Regulation is a standard regulatory filing. Since it is a specific regulatory announcement that doesn't fit perfectly into categories like Director's Dealing (DIRS) which usually refers to the formal transaction report itself, or Share Issue (SHA) which is broader, the most appropriate general regulatory filing category is RNS, as it is explicitly branded as an RNS release and deals with mandatory disclosure requirements.
2021-12-16 English
Exercise of share options and total voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services. The content explicitly details the 'Exercise of share options' by a director (Chief Scientific Officer) and provides the resulting change in total voting rights. This type of transaction report, specifically concerning insider dealings (director's share transaction), falls under the category of Director's Dealing (DIRS) or, more broadly, a regulatory announcement. Since the document details a personal transaction by a director, 'DIRS' is the most specific fit. However, the structure and the presence of the RNS header strongly suggest it is a mandatory regulatory disclosure. Given the options, 'DIRS' covers the specific content (Director's Dealing), but 'RNS' is the general category for these types of announcements on the London Stock Exchange. Since the core subject is the director's transaction, DIRS is preferred over the general RNS fallback, as DIRS is a specific type of regulatory filing. The content is not a general announcement of a report (RPA) but the report itself detailing the transaction.
2021-12-14 English
Half-year Report
Earnings Release Classification · 99% confidence The document explicitly states it is announcing the 'Half year Report' and provides 'unaudited interim results for the six months ended 30 September 2021 ("H1 FY2022")'. It contains detailed financial highlights, operational reviews, and condensed financial statements (Statement of Comprehensive Income and Statement of Financial Position) covering a period shorter than a year. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is an announcement (RPA/RNS), the core content is the comprehensive interim report itself, which is significantly longer than a typical announcement, making IR the most accurate classification. H1 2022
2021-12-06 English
Update on R&D
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content is a brief update on the company's R&D activities concerning the Omicron variant, which is a specific, non-periodic business development announcement. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a general regulatory announcement disseminated via RNS that doesn't fit into the more specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general Regulatory Filings category, RNS.
2021-12-02 English
Notice of Results
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (indicated by the RNS Number and the footer mentioning RNS, LSE, and FCA). The core content is a 'Notice of results' stating that the company 'will release its unaudited interim results for the six months ended 30 September 2021 on Monday, 6 December 2021.' It also announces an investor presentation related to these results. Since the document is an announcement about the *future release* of an interim report (which would typically be classified as 'IR'), and it is a short regulatory notice, it fits the definition of a Report Publication Announcement (RPA) or, more generally, a Regulatory Filing (RNS). Given the specific nature of announcing the release date of a report, RPA is highly appropriate, but RNS is the general category for LSE regulatory news. Since the primary action is announcing the publication of results, and it is not the results themselves, RPA is the most precise fit among the options that describe an announcement rather than the report content. However, the document is clearly a standard regulatory news service release (RNS). Given the options, RPA (Report Publication Announcement) is the best fit because it explicitly announces the publication of results, adhering to the 'MENU VS MEAL' rule.
2021-11-17 English
Grant of options
Remuneration Information Classification · 99% confidence The document is identified by the header 'RNS Number : 5751P' and contains an announcement titled 'Grant of options' to the CEO, Richard Jones. It details the issuance of options under an employee share option scheme and includes a mandatory 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them' table. This type of filing, which reports personal share transactions by directors/executives (insider trades), directly corresponds to the definition of Director's Dealing (DIRS). Although it involves shares, it is specifically about insider transactions, not a general share issue (SHA) or buyback (POS). The presence of the RNS header suggests it is a regulatory announcement, but DIRS is the most specific category.
2021-10-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.